The University of Chicago Header Logo

Connection

Gini Fleming to Chemotherapy, Adjuvant

Back to Details
This is a "connection" page, showing publications Gini Fleming has written about Chemotherapy, Adjuvant.
Gini Fleming
Connection Strength
2.164
Chemotherapy, Adjuvant
  1. Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. J Clin Oncol. 2019 09 20; 37(27):2490-2500.
    View in: PubMed
    Score: 0.588
  2. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
    View in: PubMed
    Score: 0.154
  3. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
    View in: PubMed
    Score: 0.127
  4. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
    View in: PubMed
    Score: 0.125
  5. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist. 2016 10; 21(10):1250-1259.
    View in: PubMed
    Score: 0.119
  6. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.
    View in: PubMed
    Score: 0.116
  7. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol. 2009 Apr; 36(2):145-54.
    View in: PubMed
    Score: 0.072
  8. Gemcitabine/docetaxel--welcome to a new standard. Gynecol Oncol. 2008 Jun; 109(3):313-5.
    View in: PubMed
    Score: 0.068
  9. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007 Jul 10; 25(20):2983-90.
    View in: PubMed
    Score: 0.064
  10. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006 Jun; 4(6):459-68.
    View in: PubMed
    Score: 0.059
  11. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
    View in: PubMed
    Score: 0.050
  12. Adjuvant aromatase inhibitors: are we there yet? Cancer. 2003 Nov 01; 98(9):1779-81.
    View in: PubMed
    Score: 0.049
  13. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382.
    View in: PubMed
    Score: 0.046
  14. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.
    View in: PubMed
    Score: 0.046
  15. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303.
    View in: PubMed
    Score: 0.037
  16. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019 07; 69(4):258-279.
    View in: PubMed
    Score: 0.036
  17. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. J Clin Oncol. 2019 04 10; 37(11):862-866.
    View in: PubMed
    Score: 0.036
  18. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
    View in: PubMed
    Score: 0.034
  19. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253.
    View in: PubMed
    Score: 0.031
  20. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 05 10; 34(14):1584-93.
    View in: PubMed
    Score: 0.029
  21. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015 Nov; 154(2):275-86.
    View in: PubMed
    Score: 0.028
  22. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.
    View in: PubMed
    Score: 0.028
  23. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
    View in: PubMed
    Score: 0.027
  24. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
    View in: PubMed
    Score: 0.026
  25. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100.
    View in: PubMed
    Score: 0.024
  26. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 2010 Jan 15; 116(2):355-61.
    View in: PubMed
    Score: 0.019
  27. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Mar; 116(3):301-6.
    View in: PubMed
    Score: 0.019
  28. Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer. J Natl Compr Canc Netw. 2009 May; 7(5):535-41.
    View in: PubMed
    Score: 0.018
  29. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6.
    View in: PubMed
    Score: 0.018
  30. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov; 17(11):1108-20.
    View in: PubMed
    Score: 0.017
  31. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9.
    View in: PubMed
    Score: 0.017
  32. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):1231-1241.
    View in: PubMed
    Score: 0.017
  33. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63.
    View in: PubMed
    Score: 0.011
  34. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin Breast Cancer. 2001 Jul; 2(2):138-43; discussion 144.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.